Editas Medicine, Inc.
(NASDAQ : EDIT)

( )
EDIT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-3.26%281.891.4%$836.99m
AMGNAmgen, Inc.
-0.74%219.671.3%$491.36m
CELGCelgene Corp.
0.37%110.411.3%$450.64m
GILDGilead Sciences, Inc.
-1.54%63.331.0%$378.69m
ILMNIllumina, Inc.
0.84%298.223.5%$307.89m
VRTXVertex Pharmaceuticals, Inc.
1.59%207.101.9%$294.70m
REGNRegeneron Pharmaceuticals, Inc.
-0.03%348.302.6%$261.95m
EXASEXACT Sciences Corp.
-2.08%78.2524.0%$192.05m
ALXNAlexion Pharmaceuticals, Inc.
-2.11%107.132.0%$186.15m
SGENSeattle Genetics, Inc.
1.42%112.216.1%$128.31m
BMRNBioMarin Pharmaceutical, Inc.
0.34%76.144.3%$111.10m
SRPTSarepta Therapeutics, Inc.
1.05%101.0014.6%$108.01m
AAgilent Technologies, Inc.
0.13%77.151.6%$100.15m
MRTXMirati Therapeutics, Inc.
-3.45%100.732.3%$86.01m
NBIXNeurocrine Biosciences, Inc.
-0.44%110.915.0%$83.87m

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.